Glucotrack receives second Nasdaq delisting notice for failing minimum stockholders' equity

summarizeSummary

Glucotrack received a second delisting notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, compounding its existing bid price deficiency and increasing delisting risk.

check_boxKey Events

• Second Delisting Notice Received

  Nasdaq notified Glucotrack of non-compliance with the $2.5 million minimum stockholders' equity requirement, identified from the Q1 2026 Form 10-Q.

• Additional Basis for Delisting

  This new deficiency serves as an additional and independent basis for delisting from The Nasdaq Capital Market, compounding the existing bid price rule violation.

• Appeal Process Initiated

  The company intends to request a hearing before a Nasdaq Hearings Panel by May 18, 2026, to appeal both delisting determinations, which will temporarily stay delisting actions.

auto_awesomeAnalysis

This 8-K confirms Glucotrack's precarious financial position, adding a second, independent reason for delisting from Nasdaq. The company previously received a notice for failing the minimum bid price rule. Now, Nasdaq has identified a failure to meet the $2.5 million minimum stockholders' equity requirement, as revealed in the recent 10-Q. This significantly increases the risk of delisting, despite the company's intent to appeal.